Roland Martin is a neurologist with long-term specialization in multiple sclerosis (MS). He is currently heading the MS center at the University Hospital Zurich and a translational research team at the University of Zurich. He has been pursuing research in the areas of MS pathogenesis, autoreactive T cells, antigen specificity, and the role of genetic- and environmental risk factors of MS, as well as the development of innovative treatments. The induction of antigen-specific tolerance and autologous hematopoietic stem cell transplantation are among these. Before Zurich, he worked at the University Hospitals Würzburg and Tübingen, the National Institutes of Health, Bethesda, the University Hospital Vall D'Hebron, Barcelona, and the University of Hamburg and its University Hospital. At Cellerys, he heads the immunological and biomarkers studies, which aim at providing proof-of-mechanism for antigen-specific tolerance.

Nik joined Cellerys in December 2023. He is a seasoned industry professional with 27 years of experience in drug development, program leadership, alliance management, and corporate business operations in both large pharma (F. Hoffmann-La Roche AG, Novartis AG) and biotech (Corlieve SAS, Vector BioPharma AG). He holds a PhD in biochemistry from the University of Sussex and business certification from London Business School (Senior Executive Program).

Magdalena joined Cellerys in July 2021 as Head of Regulatory Affairs. Magdalena is a scientist specialising in Regulatory Affairs and Quality Management with over 12 years of experience in clinical trial management, GCP compliance, and managing and overseeing multinational and investigator-initiated studies. After completing her doctoral degree in Clinical Immunology at the University of Freiburg (Germany), Magdalena started working as a Project Manager at CSL Behring. From there, she moved to University Hospital Zurich (Department of Neuroimmunology) & Wyss Zurich, where she has been responsible for coordination and conduct of diverse clinical trials and the implementation of the Quality System, and contributed to the regulatory and quality activities during the clinical development of the ETIMSred therapeutic approach. At Cellerys, Magdalena will drive the product compliance and regulatory preparation for the Clinical Trial as well as actively support several aspects of product development.

Nathalie is head of Administration overseeing all the back-office processes at Cellerys. In her role she can build on 14 years of experience from various similar positions in finance and operations management. She started her career at the ETH Zurich in the department finance and controlling before she then moved on to the University Hospital Zurich where she worked for the department of Neurology. There she was responsible for HR, finance and third-party funding. After that she started her new position at the University of Zurich in the Institute of Physiology as a managing director. In September 2021 she joined Cellerys AG in the role as Operations Manager. Nathalie graduated in business administration

Before joining Cellerys in early 2022, Valentin was working 4+ years at the University Children’s Hospital of Zurich, where he had broad responsibilities in the implementation and execution of experiments, lab management, patient sample biobanking, data analysis and scientific writing. Technically he was specialized in immunological assays such as flow cytometry and adaptive immune receptor repertoire sequencing. He has a diverse background with prior experience ranging from product development for medical wound dressings to ecotoxicological assessment of novel fragrance compounds in various model systems. Valentin holds a bachelor’s degree in biology from Université de Lausanne and a master’s in neurosciences at UZH.

Jacobo joined Cellerys at the start of 2022 after working as technician in the University of Zurich. Here he was the technical lead for 4i projects including working on cancer tissues for the Tumor Profiler, expanding 4i capabilities or being the point of contact for any outside collaborators. He developed expertise in a myriad of lab techniques in different areas such as microscopy, tissue handling, machinery automation and more. He also has worked for Honeywell in Portsmouth for product development and quality assurance. Jacobo studied a bachelors’ degree in biochemistry at UCL and master’s in virology at UZH.

Mireia is co-founder and co-owner of Cellerys since its foundation. Mireia is a PhD in Biological Sciences with six years of experience as post-doc in France and USA, more than fourteen years of experience as independent investigator in Germany and Switzerland, and a strong track record in human immunology. Her main areas of interest have been the identification and characterization of autoreactive CD4+ T cells with special focus on the discovery of novel autoantigens in multiple sclerosis, disease mechanisms including causes of disease heterogeneity and the development of antigen specific tolerization therapies in in this disease. She also have a Master in Scientific Communication and a Master in Nutrition and Food.

Zoe works as a PhD student at cellerys. After finishing her Bachelor degree in general biology at ETH Zürich, she continued to focus on Neuroimmunology at the University of Zurich. She completed her one-year Master’s project at the Neuroimmunology and Multiple Sclerosis (NIMS) at the University Hospital of Zurich, focusing on the role of memory B cells in Multiple Sclerosis. During her studies, Zoe has also been part of the ETH student committee for biologists as head of PR & sponsorship. She has further collected practical experience in administration and customer service at ametiq AG, a company developing a cloud-based administratory software for private practices and hospitals. During her freetime, Zoe is a passionate cook and host, and loves engaging in sports, mainly cycling.

Before joining our team, Lara studied biochemistry with a specialization in molecular medicine at the Ruhr-University Bochum and did her master's degree in interdisciplinary life sciences at the Université Paris Cité. Additionally, she gained experience as a research associate in both industry and academia in Germany and France. During her master's program, she had the opportunity to work on a wide range of scientific topics and completed three laboratory projects, involving computational multi-omics analysis and investigation of epigenetic reprogramming through DNA methylation and polycomb-group proteins, as well as polymorphisms of nuclear receptors. After discovering her passion for immunology, Lara continued her research studies at the ETH Zurich, focusing on transcriptional dynamics in T cell differentiation and T cell engineering, and works now as a PhD student at Cellerys.

Pietro studied computer science at ETH Zurich. He strives to work in multidisciplinary environments, with interests spanning the areas of digital health and machine learning applied to medical problems. Before joining Cellerys, Pietro was involved in several projects on the understanding of T cell cross-reactivity and the monitoring of multiple sclerosis with wearable sensors. Since June 2023, he supports the analysis of single-cell RNA sequencing data at Cellerys.

Laure joined Cellerys in October 2023 as a Principal Scientist, working at the interface between immunology and translational medicine. With a strong expertise in T cell biology and a keen interest in bioinformatics, Laure aims to leverage state-of-the-art technologies to explore innovative treatments. Her academic journey began with a Ph.D. and postdoctoral work in cellular immunology at the University of Lausanne, focusing extensively on T cell exhaustion. Transitioning to the industry, Laure served as an expert immunologist at Galderma in Lausanne, specializing primarily in -OMICS technologies. Moreover, collaborating with ETH's Computational Cancer Genomics group, Laure further developed new competencies in bioinformatics. Beyond her professional endeavors, Laure enjoys biking and reading fantasy, science fiction and history books. She also values engaging in long and stimulating discussions with friends

At Novartis, our purpose is to reimagine medicine to improve and extend people's lives. We use innovative science and technology to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company. www.novartis.com/research-development

Neogap Therapeutics is a privately held biopharmaceutical company with a focus on immune-oncology based at the Centre for Molecular Medicine at Karolinska Institutet, Stockholm, Sweden. Neogap and Cellerys have launched a collaboration with the aim of using Neogap’s EpiTCer technology to detect rare autoreactive CD4+ T cells in multiple sclerosis patients. The EpiTCer-based monitoring of autoreactive T cells will be a key aspect of Cellerys’ multi-center Phase II clinical trial.

As a flexible partner with more than 20 years of experience in the development and production of ATMPs, TETEC supports biotech & pharma companies that are entering the clinical stage with their developmental cell therapies.

Our specialists provide extensive know-how and expertise in technical transfer processes, manufacturing, clinical trial setup & management as well as registration of ATMPs, blood products, autologous cell therapies and biohybrid product solutions. Please feel free to contact us under cdmo@tetec-ag.de to find out more!

With its 28,000 enrolled students, the University of Zurich (UZH) is Switzerland's largest university. Founded in the year 1833, UZH was Europe’s first university to be established by a democratic political system. Today, UZH is one of the leading universities in the German-speaking world. Made up of seven faculties covering some 100 different subject area.

Numerous awards the University’s international reputation in the fields of medicine, including immunology, genetics, neuroscience and structural biology as well as in economics. To date, the Nobel Prize has been awarded on twelve UZH scientists.

The Wyss Zurich Translational Center – Wyss Zurich – is a joint accelerator of the University of Zurich and ETH Zurich (Swiss Federal Institute of Technology Zurich), which was made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. h.c. mult. Hansjörg Wyss. It was established to foster translational research focused on developing treatment protocols and clinical therapies, as well as novel technologies and intelligent systems, in the emerging fields of Regenerative Medicine, Robotics, and to related hybrid technologies. Wyss Zurich unites world-leading experts from both institutions in multidisciplinary teams, pooling their knowledge and expertise. For more information, please visit www.wysszurich.ch